Search Results - "Turkistani, F."

PRICE ANALYSIS OF THERAPEUTIC BIOLOGICS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION (1986–OCTOBER 2015) by Turkistani, F, Alotaibi, A, Alnafesah, A, Seoane-Vazquez, E

Get full text

PND67 COMPARISON OF MULTIPLE SCLEROSIS DRUG PRICES IN SAUDI ARABIA VS. UNITED ARAB OF EMIRATES by Turkistani, F., Bin Sawad, A.

Get full text

PNS51 HEALTHCARE RESOURCE INDICATORS: THE WORLDWIDE TOP 3 COUNTRIES WITH THE MOST PHYSICIANS PER CAPITA VS. SAUDI ARABIA by Turkistani, F., Bin Sawad, A.

Get full text

ND3 ORPHAN DRUG MARKET ACCESS CHALLENGES IN EUROPEAN UNION FIVE by Bin Sawad, A., Turkistani, F.

Get full text

RWD121 Baseline Characteristics of Patients Prior to Oriahnn Prescription by Turkistani, F, Johns, B, Pinsky, B

Get full text

RWD48 Economic Burden Associated With Sobriety Restrictions to Direct-Acting Antiviral Access Among Medicaid Patients With Hepatitis C Virus: A Retrospective Analysis of Claims from States With and Without Restrictions by Martin, MT, Rajagopalan, K, Makhija, D, Turkistani, F, Burk, C, Rock, M, Reau, N

Get full text

RWD145 Healthcare Resource Utilization (HCRU) and Costs Among Previously-Treated Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Retrospective Analysis of SEER-Medicare Linked Claims by Rai, P, Paratane, D, Turkistani, F, Min, J, Rajagopalan, K, Hu, X

Get full text

RWD188 Healthcare Cost and Healthcare Resource Utilization (HCRU) Among First-Line (1L) Treated Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC): Analysis of Seer-Medicare Linked Claims in the US by Rai, P, Turkistani, F, Momo, H, Min, J, Syed, SS, Paratane, D, Rajagopalan, K, Aggarwal, H

Get full text

CO192 A Retrospective Database Analysis of US Medicaid Treatment-Naive People With HIV (PWH) With or Without Mental Health Disorders (MHDs) Initiating Single-Tablet Regimens (STRs) Vs. Multi-Tablet Regimens (MTRs) by Chen, M., Turkistani, F., Weinberg, AR, Christoph, MJ, Gruber, J., Trom, C., Park, S., Rajagopalan, K.

Get full text

PCN276 - Continental Comparison of Innovative Drugs Prices, The Case of Oncology Used for Treatment of Solid Tumors in Germany and The United States by Aissaoui, N, Bin Sawad, A, Turkistani, F

Get full text

Continental Comparison of Innovative Drugs Prices, The Case of Oncology Used for Treatment of Solid Tumors in Germany and The United States by Aissaoui, N, Bin Sawad, A, Turkistani, F

Get full text

FINANCIAL INFLUENCE OF CURRENT AND ALTERNATIVE PRICING BENCHMARKS FOR PHARMACY DISPENSED MEDICATIONS IN CALIFORNIA WORKERS’ COMPENSATION SYSTEM by Wilson, L, Turkistani, F, Huang, W, Tran, DM

“…OBJECTIVES: California's Workers' Compensation (CWCS) questioned adequacy of current Medi-Cal pricing benchmark and requested analysis of alternatives that…”
Get full text

Pivotal Studies of Oncology Drugs Approved in Europe, Which Evidence Based-Medicine? by Aissaoui, A, Turkistani, F, Bin Sawad, A, Aissaoui, N

Get full text

Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials by Aissaoui, A, Bin Sawad, A, Turkistani, F, Aissaoui, N

Get full text

PCN52 - Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials by Aissaoui, A, Bin Sawad, A, Turkistani, F, Aissaoui, N

Get full text

PCN48 - Pivotal Studies of Oncology Drugs Approved in Europe, Which Evidence Based-Medicine? by Aissaoui, A, Turkistani, F, Bin Sawad, A, Aissaoui, N

Get full text

PHP79 - PRICE ANALYSIS OF THERAPEUTIC BIOLOGICS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION (1986–OCTOBER 2015) by Turkistani, F., Alotaibi, A., Alnafesah, A., Seoane-Vazquez, E.

Get full text

AVAILABILITY OF ECONOMIC DATA FOR THERAPEUTIC BIOLOGIC DRUGS IN THE US by Turkistani, F, Seoane-Vazquez, E, Rodriguez-Monguio, R, Bin, Sawad A

“…OBJECTIVES: 1) to evaluate changes in product package inserts (PPIs) labeling and indications, 2) to evaluate the availability of economic evaluations…”
Get full text

APPROVALS AND DISCONTINUATIONS OF NEW MOLECULAR ENTITIES AND THERAPEUTIC BIOLOGIC LICENSE APPLICATIONS IN THE UNITED STATES by Turkistani, F, Seoane-Vazquez, E, Rodriguez-Monguio, R, Bin, Sawad A

“…OBJECTIVES: The objective of this study was to describe trends in approvals and discontinuations of new molecular entities (NME) and therapeutic biologic…”
Get full text

PRICE ANALYSIS OF THERAPEUTIC BIOLOGICS MARKETED IN THE UNITED STATES by Turkistani, F, Seoane-Vazquez, E, Rodriguez-Monguio, R, Bin, Sawad A

“…OBJECTIVES: The objective of this study was to evaluate trends in manufacturer-listed prices of therapeutic biologies approved by the FDA for chronic use and…”
Get full text